Artery Wall Assessment Helps Predict Kidney Transplant Outcome

Domingo Hernández1*, Javier Triñanes2*, Eduardo Salido2, Sergio Pitti3, Margarita Rufino4, José Manuel González-Posada4, Armando Torres4

1 Nephrology Department, Carlos Haya Regional University Hospital and University of Málaga (IBIMA), REDinREN, Málaga, Spain, 2 Research Unit, Hospital Universitario de Canarias, Tenerife, Spain, 3 Radiology Department, Hospital Universitario de Canarias, Tenerife, Spain, 4 Nephrology Department, Hospital Universitario de Canarias, CIBICAN, University of La Laguna, Instituto Reina Sofía de Investigación Renal (IRSIN), Tenerife, Spain

* These authors contributed equally to this work.
* domingohernandez@gmail.com

Abstract

Background
Kidney transplant recipients have high cardiovascular risk, and vascular inflammation may play an important role. We explored whether the inflammatory state in the vessel wall was related to carotid intima-media thickness (c-IMT) and patient survival following kidney transplantation.

Methods
In this prospective observational cohort study we measured c-IMT and expression of proinflammatory cytokines and adhesion molecules in the inferior epigastric artery in 115 kidney transplant candidates. Another c-IMT measurement was done 1-year post-transplantation in 107. By stepwise multiple regression analysis we explored factors associated with baseline c-IMT and their changes over time. Multivariate Cox regression analysis was constructed to identify risk factors for mortality.

Results
A worse cardiovascular profile (older age, smoker, diabetic, carotid plaque, systolic blood pressure and vascular calcification) and higher VCAM-1 levels were found in patients in the highest baseline c-IMT tertile, who also had a worse survival. Factors independently related to baseline c-IMT were age ($\beta=0.369$, $P<0.0001$), fasting glucose ($\beta=0.168$, $P=0.045$), smoking ($\beta=0.228$, $P=0.003$) and VCAM-1 levels ($\beta=0.244$, $P=0.002$). Independent factors associated with c-IMT measurement 1-year post-transplantation were baseline c-IMT ($\beta=-0.677$, $P<0.0001$), post-transplant diabetes ($\beta=0.225$, $P=0.003$) and triglycerides ($\beta=0.302$, $P=0.023$). Vascular VCAM-1 levels were associated with increased risk of mortality in bivariate and multivariate Cox regression. Notably, nearly 50% of patients showed an increase or maintenance of high c-IMT 1 year post-transplantation and these patients experienced a higher mortality (13 versus 3.5%; $P=0.021$).
Conclusion

A worse cardiovascular profile and a higher vascular VCAM-1 protein levels at time of KT are related to subclinical atheromatosis. This could lead to a higher post-transplant mortality. Pre-transplant c-IMT, post-transplant diabetes and triglycerides at 1-year post-transplantation may condition a high c-IMT measurement post-transplantation, which may decrease patient survival.

Introduction

Chronic kidney disease (CKD) is an independent risk factor for cardiovascular disease (CVD) and premature death, primarily due to acceleration of the atheromatosis process [1, 2]. Although traditional cardiovascular risk factors are highly prevalent in CKD patients, they do not completely explain the elevated risk, suggesting that other mechanisms may be crucial. Indeed, both endothelial dysfunction and vascular inflammation are processes involved in the development of atheromatosis in renal patients, especially when traditional and uremia-related risk factors concur [3–5].

Atheromatosis is a dynamic and complex inflammatory process of the artery wall. The endothelium overlying atherosclerotic lesions may express vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), the monocyte chemoattractant protein-1 (MCP-1) and interleukin-6 (IL-6), which have all been shown to be closely linked with infiltration and proliferation of atheromatosis-related inflammatory cells [6–8]. These soluble molecules are predictors of cardiovascular mortality in both CKD patients and kidney transplant (KT) recipients [3–5, 9, 10], but their expression in the artery wall has not been assessed. In addition, the relationship between the soluble inflammatory markers (including C-reactive protein) at the time of KT and the evolution of post-transplant atherosclerosis is controversial [11], suggesting that increased cardiovascular mortality in these patients may be explained by a higher pre-transplant atherosclerotic burden. We hypothesized, therefore, that artery wall assessment at the time of transplantation could better elucidate the pathophysiologic relationship between atheromatosis-associated pre-transplant inflammatory state and the evolution of post-transplant atherosclerosis, which could help to predict long-term survival.

Common carotid artery intima media thickness (c-IMT) is an early marker of subclinical atheromatosis, which correlates with an increased risk of CVD in both the general population and renal patients, including KT recipients [12, 13]. Nevertheless, few studies have examined the precise relationship between c-IMT measurements and pro-inflammatory cytokines and adhesion molecules involved in the atherogenic process of KT recipients, clinical setting where multiple classical and non-traditional risk factors are present. In addition, there are no conclusive data regarding the impact of changes over time in the c-IMT on adverse outcomes after KT [14–18].

This cohort study was performed to determine whether the in vivo expression levels of proinflammatory cytokines and adhesion molecules were associated with c-IMT at the time of KT. We also proposed to explore whether the inflammatory state in the vessel wall was related to c-IMT after the first post-transplant year and long-term patient survival following KT.
Materials and Methods

Participants and tissue samples

This prospective observational cohort study evaluated 148 consecutive adult CKD patients who received a deceased KT between August 2007 and April 2009 in a regional transplant center (Hospital Universitario de Canarias, Tenerife, Spain). We excluded 33 patients who were unable to undergo a perioperative carotid echography study. Thus, the final study population comprised 115 CKD patients who underwent a baseline echographic study at the time of KT. All the patients received conventional immunosuppression (steroids, tacrolimus and mycophenolate mofetil). During the first post-transplant year, 5 patients died and 3 experienced graft loss. Thus, 107 underwent a second carotid echography study 12 months after KT. Part of the methodology of this study has been reported previously [5]. Relevant clinical information about the donors and recipients was extracted prospectively from the Canary Islands Renal Transplant database, which has been updated yearly since 1996 [19]. The study was purely descriptive, and no attempts were made to modify any therapeutic aspect. Medical record review was performed according to the Spanish law.

The study was approved by the ethics committee of the Hospital Universitario de Canarias (Tenerife, Spain) and conducted following the Declaration of Helsinki and Istanbul. Written informed consent was obtained from all patients.

During surgery, a sample of the inferior epigastric artery (IEA) was obtained from all the participants. Tissue was quickly dissected in three sections for the different analyses: gene expression, protein quantification and histological analysis. Artery segments were fixed, paraffin-embedded and processed as previously reported [5]. Briefly, the reduction in arterial lumen was calculated as the percentage of lumen lost from the total lumen area measured at the inner elastic lamina, and the fibrosis as the proportion of the total area, including media and intima layers, positive for Sirius red staining. MCP-1, IL-6, ICAM-1 and VCAM-1 expression was ascertained by immunohistochemistry on serial sections as described [5]. All images were taken with a microscope Olympus DX41 (Tokyo, Japan) fitted with a Canon DP72 camera (Tokyo, Japan), and then analyzed using the software ImageJ (NIH) and the plug-in WCIF from Western Research Institute (Toronto, Canada).

The relative mRNA abundance was quantified using quantitative PCR (qPCR) and the SYBR Green detection method, as described [5], using total RNA isolated from EIA fragments similar to those used for immunohistochemistry. Real-time monitoring of the amplification process was performed with the iQ5 system (Bio-Rad, California, USA) and expression of each gene was normalized with the reference genes (18S rRNA and RNase P). The data were analyzed using the qBASE software [20].

Finally, another fragment of EIA was lysed in RIPA buffer and the quantification of IL-6, MCP-1, ICAM-1 and VCAM-1 was determined by using xMAP technology, as described [5]. The concentration of each analyte was determined for each sample and then corrected for the total protein concentration; the result obtained is expressed as picograms of analyte per microgram of total protein.

c-IMT measurements

The baseline c-IMT was determined within 2 weeks after surgery by an experienced radiologist (SP) blinded to clinical data according to the standard clinical procedure [13], using a SSA-380 ultrasound transducer (Toshiba, Tokyo, Japan). Either an L6-7 MHz or a linear array transducer was used depending on the artery depth. Measurements of the left and the right common carotid were obtained in both the sagittal and axial insonation planes. The highest thickened
A diffuse point without plaques was selected for measurement and the mean value was used for analysis. A second carotid echographic study was performed 12 months after KT by the same radiologist. A low intraobserver variability has previously been reported in our radiology section after repeated measurements (mean intraclass concordance correlation 0.96 [95% CI 0.90–0.99]; P<0.001) [13]. Lastly, the presence of carotid plaques was also recorded.

**Outcome**

All-cause mortality and graft loss were recorded. The last follow-up was on December 31, 2013. Survival was measured in months from the date of transplantation.

**Statistical analysis**

Baseline c-IMT measurements were divided into tertiles in order to assess the clinical characteristics. After the second echographic study, patients were clustered in two groups (from the nine possible combinations) according to the fluctuation between the c-IMT tertiles at both time points (Fig 1). Group I: individuals who changed to a lower tertile or who maintained both values within the lower or the middle tertile were classified as “decrease or stable low-middle stable”; and Group II: individuals who increased to the next tertile or with both values within the highest tertile were labeled as “increase or high stable”. Data are expressed as mean±SD (normally distributed data), median and interquartile range (non-normally distributed data) or as percent frequencies. Inter-group comparisons of quantitative variables were made by Student t test or the Mann-Whitney U-test as appropriate. ANOVA (or the Kruskal-Wallis test as appropriate).

![Figure 1. Variation patterns of c-IMT tertiles according to the fluctuation between the c-IMT measurements during study.](https://example.com/figure1.png)
appropriate) was used to compare continuous variables between different tertiles. The Bonferroni procedure was used for multiple comparisons of equivalence. Categorical data were compared using the chi-square test and Fisher exact test as appropriate. Simple correlations were explored with the Spearman coefficient. Stepwise multiple regression analysis was performed to determine independent factors associated with both baseline and final c-IMT measurements. The Kaplan-Meier test was used for survival analysis. Univariate, bivariate (models adjusting for other risk factors considered one by one) and multivariate Cox regression (entering risk factors two by two) were performed to identify risk factors for mortality. Calculations were made using the SPSS statistical package 15.0 (SPSS, Chicago, IL). *P* values <0.05 were considered significant.

### Results

#### Baseline c-IMT measurements and clinical characteristics

*Table 1* shows the clinical characteristics and biochemical data for the different baseline c-IMT tertiles. As expected, age, smoking, and proportion of diabetics were significantly higher in the highest c-IMT tertile. Although a good blood pressure control was achieved in the c-IMT tertiles, systolic blood pressure was nevertheless significantly higher in the highest tertile. Accordingly, fasting glucose and HbA1c levels, as well as the number of patients with major vascular calcifications and carotid plaque, were increased significantly in the highest c-IMT tertile. In addition, fasting glucose levels correlated with baseline c-IMT measurements (*rho* = 0.47; *P* < 0.0001) (**S1 Fig**). Finally, baseline c-IMT measurements correlated with the presence of baseline carotid plaques (*rho* = 0.354; *P* < 0.0001). No significant differences were found between the different tertiles in other clinical parameters, including the use of statins, aspirin, beta-blockers, and renin-angiotensin system blockers (*Table 1*).

#### Artery wall pathological changes

Overall histopathological analysis showed a greater degree of lumen reduction in the IEA among patients in the highest c-IMT tertile (*Table 1*), and this luminal narrowing was age dependent (*rho* = 0.34, *P* = 0.004). A trend toward a greater proportion of fibrosis in the intima was observed in the highest c-IMT tertile. Additionally, c-IMT measurements correlated with the degree of arterial lumen narrowing (*rho* = 0.416, *P* < 0.0001). As previously reported [5], the intimal thickening for the IEA was mostly composed of smooth muscle actin (SMA)-positive cells and collagen fibers. No intimal calcification was observed in any IEA sample, while a higher incidence and severity of calcification in the media layer was present in the highest c-IMT tertile (*Table 1*). Finally, medial calcification was significantly associated with age (*rho* = 0.46, *P* = 0.001) and fasting glucose (*rho* = 0.55, *P* < 0.0001) in all the patients. After excluding diabetic patients, only age showed a correlation with medial calcification (*rho* = 0.39, *P* = 0.001).

#### Proinflammatory cytokines, adhesion molecules and c-IMT

Although a trend toward a higher mRNA expression of ICAM-1 in the IEA was only observed in the highest c-IMT tertile, the VCAM-1 protein levels were significantly increased in the highest c-IMT tertile compared with the rest (**Fig 2**). No significant differences were observed for the expression of IL-6 or MCP-1 between tertiles. Interestingly, when vascular VCAM-1 protein levels were divided into tertiles, age, c-IMT measurements, as well as a major proportion of cardiovascular disease and carotid plaques disease were significantly increased in the highest VCAM-1 tertile (*Table 2*). Likewise, a major degree of arterial lumen reduction was observed among patients in the highest VCAM-1 tertile, and this luminal narrowing correlated with the vascular VCAM-1 protein levels (*rho* = 0.339, *P* < 0.0001). Accordingly, VCAM-1...
| Cause of CKD (%) | T1 (N = 39) | T2 (N = 38) | T3 (N = 38) |
|------------------|-------------|-------------|-------------|
| Diabetes         | 7.7         | 18          | 34          |
| Glomerulonephritis | 23         | 16          | 10.5        |
| Polycystic kidney disease | 13         | 31          | 10.5        |
| Nephroangiosclerosis | 2.6         | -           | 2.6         |
| Other            | 51          | 24          | 37          |
| Body mass index (kg/m²) | 24.4±4     | 26±4        | 26.2±5      |
| Time on dialysis (mo) | 22±31      | 30±31       | 27±26       |
| Use of ACEI/ARA (%) | 15         | 10.5        | 10.5        |
| Use of aspirin (%) | 23         | 30          | 16          |
| Use of statins (%) | 15.4       | 24          | 21          |
| Smokers (%)      | 18          | 26          | 50          |
| Fasting glucose (mg/dL) | 98±14       | 120±38d      | 131±42b     |
| HbA1c (%)        | 5.3±0.7     | 6.1±1.1     | 6.3±1.1e    |
| Hypertension (%) | 95          | 92          | 95          |
| Systolic blood pressure (mmHg) | 130±18     | 134±17      | 141±14d     |
| Diastolic blood pressure (mmHg) | 73±5       | 75±9        | 77±9        |
| Total cholesterol (mg/dL) | 135±34     | 132±32      | 138±36      |
| HDL-cholesterol (mg/dL) | 41±12      | 42.5±15     | 39±12       |
| LDL-cholesterol (mg/dL) | 75±31      | 66±26       | 59±25       |
| Triglycerides (mg/dL) | 139±67     | 142±65      | 149±57      |
| Media layer calcification (%) | 22.6       | 47          | 70          |
| Degree of fibrosis in the intima (%) | 0.52±0.2 | 0.50±0.2 | 0.55±0.2 |
| Degree of lumen reduction of IEA (%) | 5.4±10 | 10.8±13 | 18±19g |
| Cardiovascular, n | -           | 2           | 6           |
| Infection, n     | 1           | 1           | 2           |
| Neoplasia, n     | -           | 1           | 1           |
| Other, n         | -           | 1           | -           |

Death-censored graft failure (%) 7.7 13 10.5 0.735

Abbreviations: c-IMT, carotid intima-media thickness; CKD, chronic kidney disease; ACEI/ARA, angiotensin-converting enzyme inhibitor/angiotensin receptor antagonist; IEA, inferior epigastric artery.

aP<0.0001 vs. T2 and T1;
bP<0.0001 vs. T1;
cP = 0.033 vs T2;
dP = 0.012 vs. T1;
eP = 0.006 vs. T1;
fP = 0.023 vs. T1;
gP = 0.001

doi:10.1371/journal.pone.0129083.t001
protein levels correlated with both baseline c-IMT measurements (rho = 0.380, P < 0.0001) (S1 Fig) and the presence of baseline carotid plaques (rho = 0.339, P < 0.0001). A similar correlation was also observed after excluding diabetic patients. Finally, VCAM-1 protein levels were significantly higher in patients with baseline carotid plaques compared with the rest (3.1 ± 0.4 vs. 2.7 ± 0.4 log pg/μg of total protein; P < 0.0001).

By backward multiple regression analyses, age (standardized β = 0.369, P < 0.0001), fasting glucose (standardized β = 0.168, P = 0.045), smoking (standardized β = 0.228, P = 0.003) and VCAM-1 protein levels (standardized β = 0.244, P = 0.002) were independently associated with baseline c-IMT. Overall, the model explained 41% of the c-IMT measurements. Importantly, when diabetic patients were excluded VCAM-1 protein levels maintained an independent association with baseline c-IMT (standardized β = 0.222, P = 0.013) after adjusting for confounders.

Fig 2. Proinflammatory cytokines, adhesion molecules and c-IMT measurements. A) Differences in the gene expression of proinflammatory markers in the artery wall according to c-IMT tertiles. B) Differences in the quantification of proinflammatory proteins by c-IMT tertiles. * ANOVA test for VCAM-1, P = 0.003; Bonferroni procedure, T3 vs. T1, p = 0.003; T3 vs T2, P = 0.076.

doi:10.1371/journal.pone.0129083.g002
### Table 2. Baseline clinical and pathological data of the artery wall in kidney transplant candidates according to VCAM-1 protein level tertiles.

|                                | T1 (N = 39) | T2 (N = 38) | T3 (N = 38) | P value |
|--------------------------------|-------------|-------------|-------------|---------|
| Log VCAM-1 tertile (pg/μg)     | <2.5        | 2.5 to 3.1  | >3.1        | -       |
| Mean log VCAM-1 (pg/μg)        | 2.1±0.2b    | 2.8±0.2b    | 3.4±0.2b    | 0.000   |
| Mean c-IMT (mm)                | 0.54±0.2    | 0.58±0.2d   | 0.71±0.2e   | 0.001   |
| Carotid plaques (%)            | 17          | 24          | 54          | 0.003   |
| Age (years)                    | 45.3±15     | 45.4±12d    | 53±9e       | 0.021   |
| Male (%)                       | 69          | 64          | 75          | 0.593   |
| Type of dialysis (% hemodialysis) | 69         | 85          | 89          | 0.094   |
| Pretransplant cardiovascular disease (%) | 6   | 8           | 28          | 0.014   |
| Cause of CKD (%)               |             |             |             | 0.227   |
| Diabetes                       | 6           | 25          | 28          |         |
| Glomerulonephritis             | 28          | 7           | 14          |         |
| Polycystic kidney disease      | 25          | 20          | 11          |         |
| Nephroangiosclerosis           | 3           | 5           | 8           |         |
| Other                          | 37          | 38          | 36          |         |
| Body mass index (kg/m²)        | 25.8±4      | 25.7±5      | 24.7±5      | 0.568   |
| Large vascular calcifications (%) | 22         | 24          | 44          | 0.051   |
| Time on dialysis (mo)          | 23±34       | 28±30       | 30±27       | 0.642   |
| Use of ACEI/ARA (%)            | 15          | 13          | 11          | 0.858   |
| Use of aspirin (%)             | 17          | 14          | 36          | 0.158   |
| Use of statins (%)             | 12          | 15          | 33          | 0.064   |
| Smokers (%)                    | 28          | 28          | 31          | 0.967   |
| Fasting glucose (mg/dL)        | 108±37      | 118±38      | 124±35      | 0.182   |
| HbA1c (%)                      | 5.4±0.7     | 5.9±0.1     | 6.1±1.1     | 0.166   |
| Hypertension (%)               | 97          | 92          | 92          | 0.643   |
| Systolic blood pressure (mmHg) | 132±21      | 133±14      | 139±16      | 0.195   |
| Diastolic blood pressure (mmHg) | 72±7       | 77±8        | 77±9        | 0.055   |
| Total cholesterol (mg/dL)      | 138±35      | 136±36      | 135±32      | 0.963   |
| HDL-cholesterol (mg/dL)        | 44±16       | 42±13       | 39±11       | 0.502   |
| LDL-cholesterol (mg/dL)        | 75±38       | 66±28       | 63±23       | 0.483   |
| Triglycerides (mg/dL)          | 118±54      | 159±77g     | 147±45      | 0.019   |
| Media layer calcification (%)  | 38          | 48          | 62          | 0.152   |
| Degree of fibrosis in the intima (%) | 0.52±0.2   | 0.54±0.2   | 0.53±0.1   | 0.856   |
| Degree of lumen reduction of IEA (%) | 4.3±7   | 9.1±10h    | 21±20i     | 0.000   |
| Death (%)                      | 5           | 9           | 27          | 0.088   |
| Cardiovascular, n              | 2           | 1           | 5           |         |
| Infection, n                   | -           | 1           | 3           |         |
| Neoplasia, n                   | -           | 1           | 1           |         |
| Other, n                       | -           | -           | 1           |         |
| Death-censored graft failure (%) | 11         | 14          | 7           | 0.551   |

Abbreviations: c-IMT, carotid-intima-media thickness; CKD, chronic kidney disease; ACEI/ARA, angiotensin-converting enzyme inhibitor/angiotensin receptor antagonist; IEA, inferior epigastric artery.

*a*P<0.0001 vs. T2 and T1;

*b*P<0.0001 vs. T1 and T3;

*c*P = 0.001 vs. T1;

*d*P = 0.010 vs. T3;

*e*P = 0.042 vs. T2;

*f*P = 0.054 vs. T1;

*g*P = 0.016 vs. T1;

*h*P = 0.0001 vs. T1;

*i*P = 0.002 vs. T3.

doi:10.1371/journal.pone.0129083.t002
Follow-up and outcome

After a median follow-up of 68 months (interquartile range 57–73) the overall mortality and death-censored graft failure rates were 13% and 10.4%, respectively. Patients in the highest c-IMT tertile showed a higher mortality rate compared with the middle and lower c-IMT tertiles (23.7 vs. 13.2 vs. 2.6%, respectively) (Table 1). Overall Kaplan-Meier survival estimates showed significant differences between c-IMT tertiles (log-rank analysis 7.3; \( P = 0.025 \)) (S2 Fig). In addition, patients in the highest VCAM-1 tertile showed a trend toward a lower survival compared with the rest (77 vs. 89 vs. 93%, respectively) (log-rank analysis 4.8; \( P = 0.089 \)) (S3 Fig). CVD was the leading cause of death (Table 1). By contrast, death-censored graft failure rates were comparable among study groups and chronic allograft failure was the main cause of graft failure in survivors.

Table 3 depicts the general clinical characteristics in the two groups according to the tertile variation after the second echographic study. Classical cardiovascular risk factors were more

|                      | Group I (N = 57) Decrease or low-middle stable group | Group II (N = 50) Increase or high stable group | \( P \) value |
|----------------------|-----------------------------------------------------|-----------------------------------------------|-------------|
| c-IMT (mm)           | 0.52±0.1                                            | 0.79±0.2                                      | 0.000       |
| Carotid plaques (%)  | 22                                                  | 60                                            | 0.000       |
| Age (years)          | 44.4±14                                             | 50.7±11                                       | 0.010       |
| Male (%)             | 70                                                  | 60                                            | 0.741       |
| Pretransplant CVD (%)| 11                                                  | 12                                            | 0.863       |
| Large vascular calcifications (%) | 21                                      | 35                                            | 0.116       |
| Diabetics prior to KT (%) | 10.5                 | 28                                            | 0.021       |
| Time on dialysis (mo) | 23±16                                             | 27±34                                         | 0.421       |
| Use of ACEI/ARA (%)  | 16                                                  | 9                                             | 0.337       |
| Use of aspirin (%)   | 30                                                  | 18.5                                          | 0.306       |
| Use of statins (%)   | 21                                                  | 19                                            | 0.816       |
| Acute rejection (%)  | 25                                                  | 18                                            | 0.449       |
| Smokers (%)          | 23                                                  | 39                                            | 0.094       |
| NODAT (%)            | 5                                                   | 20                                            | 0.036       |
| Fasting glucose at 1st year (mg/dL) | 105±29                              | 131±43                                         | 0.007       |
| HbA1c at 1st year (%)| 5.8±1.2                                            | 5.9±1                                         | 0.948       |
| Hypertension at 1st year (%) | 70                                 | 80                                            | 0.291       |
| Systolic blood pressure (mmHg) | 133±14                      | 130±15                                         | 0.287       |
| Diastolic blood pressure (mmHg) | 75±11                  | 73±7                                          | 0.304       |
| Total cholesterol at 1st year (mg/dL) | 174±34                 | 175±34                                         | 0.932       |
| Triglycerides at 1st year (mg/dL) | 117±45                     | 143±71                                         | 0.053       |
| Serum creatinine at 1st year (mg/dL) | 1.3±0.4                  | 1.2±0.3                                        | 0.786       |
| Total proteinuria at 1st y. (g/day) | 0.2±0.3                 | 0.25±0.3                                      | 0.593       |
| Media layer calcification (%) | 33                       | 55.6                                          | 0.009       |
| Death (%)            | 1.8                                                 | 17.6                                          | 0.043       |
| Cardiovascular, n    | 1                                                   | 5                                             |             |
| Infection, n         | 1                                                   | 2                                             |             |
| Neoplasia, n         | -                                                   | 1                                             |             |
| Death-censored graft failure (%) | 7                                      | 9.8                                           | 0.734       |

Abbreviations: c-IMT, carotid intima-media thickness; CVD, cardiovascular disease; KT, kidney transplantation; ACEI/ARA, angiotensin-converting enzyme inhibitor/angiotensin receptor antagonist; NODAT, new onset diabetes after transplantation.

doi:10.1371/journal.pone.0129083.t003
prevalent in Group II compared with Group I. Notably, new onset diabetes after transplantation (NODAT) within the first post-transplant year developed more frequently in Group II and fasting glucose at 1 year post-transplantation correlated with the final c-IMT (S1 Fig). Thus, triglyceride levels at the first post-transplant year were significantly higher in Group II. These patients had a greater proportion of intima-media fibrosis in the IEA (0.57±0.16 vs. 0.48 ±0.2; \( P = 0.034 \)), media layer calcification (56 vs. 33%; \( P = 0.031 \)) and a higher reduction of arterial lumen (14.5±18 vs. 6.6±8; \( P = 0.009 \)) compared with Group I. A trend toward higher VCAM-1 protein levels was observed in Group II (2.9±0.4 vs. 2.7±0.4 log pg/\( \mu \)g; \( P = 0.096 \)). No significant differences were observed in other clinical, pathological or inflammatory parameters between the groups. Again, VCAM-1 protein levels were only significantly correlated with the final c-IMT (S1 Fig). By backward multiple regression analysis, baseline c-IMT (standardized \( \beta = 0.742, P<0.0001 \)), NODAT (standardized \( \beta = 0.186, P = 0.003 \)) and triglycerides at the first year post-transplantation (standardized \( \beta = 0.148, P = 0.023 \)) were independently associated with the final c-IMT measurement.

After the second echographic study, 10 patients died and 9 had graft failure. Kaplan-Meier estimates showed that Group II patients experienced a significantly higher mortality compared with Group I during the follow-up (Fig 3). Notably, higher VCAM-1 protein levels were observed in the patients who died during the follow-up compared with the survivors (3.2±0.5 vs.
2.7±0.4 log pg/μg; \( P = 0.003 \). Interestingly, bivariate Cox regression analysis showed that VCAM-1 protein levels were a strong predictor of death after adjustments for potential confounders, including both baseline and final c-IMT measurements (Table 4). Finally, age, time on dialysis and VCAM-1 protein levels also remained independently associated with mortality in multivariate Cox regression analysis entering all the risk factors considered in the bivariate analysis two by two (Table 4).

### Discussion

This study shows that, in the presence of both traditional and uremia-related risk factors, VCAM-1 production in the IEA may be a marker for the development of more severe atheromatous lesions and a higher c-IMT in unselected KT candidates. Certainly, we cannot prove a causal role of VCAM-1 for atherosclerosis in this particular population. However, our data provide light on a pathogenic mechanism involved in the inflammation-related atheromatosis process at the artery wall of these patients, which could be a relevant predictor of survival following KT. To our knowledge, this is the first study designed to elucidate the impact of the production of VCAM-1 in the IEA on both c-IMT measurements and survival in KT recipients with different degrees of subclinical atheromatosis at transplantation. Furthermore, ongoing changes in the c-IMT 12 months after KT provided prognostic clinical information. The mean c-IMT of our study population was similar to that of other Caucasian populations, as was the distribution of c-IMT in tertiles [14, 21].

### Table 4. Relationship between VCAM protein levels and overall mortality by bivariate and multivariate Cox regression analysis

| Adjusted for | Hazard ratio (95% CI) | \( P \) value | Variables | Hazard ratio (95% CI) | \( P \) value |
|-------------|-----------------------|----------------|-----------|-----------------------|----------------|
| Age         | 4.5 (1.3–15)          | 0.015          | Age       | 1.07 (1.01–1.14)      | 0.038          |
| Gender      | 5.5 (1.6–18)          | 0.006          | Time on dialysis | 1.02 (1.01–1.03)      | 0.004          |
| Body mass index | 5.9 (1.7–20)       | 0.004          | Log VCAM-1 | 6.6 (1.5–30)          | 0.019          |
| Smoking     | 6.1 (1.7–22)          | 0.005          |           |                       |                |
| Baseline c-IMT | 3.5 (1.01–13)       | 0.050          |           |                       |                |
| Highest baseline c-IMT tertile | 4.2 (1.1–15) | 0.033          |           |                       |                |
| Final c-IMT | 4.5 (1.2–16)          | 0.024          |           |                       |                |
| Highest final c-IMT tertile | 4 (1.1–14)          | 0.028          |           |                       |                |
| Pretransplant diabetes | 5.6 (1.6–19)   | 0.007          |           |                       |                |
| Pretransplant CVD | 4.5 (1.3–15)     | 0.014          |           |                       |                |
| Baseline systolic blood pressure | 6.5 (1.5–27) | 0.011          |           |                       |                |
| Time on dialysis | 6.1 (1.7–21) | 0.006          |           |                       |                |
| Hemodialysis (vs. PD) | 5.2 (1.5–18) | 0.011          |           |                       |                |
| Large VC    | 3.6 (1.2–11)          | 0.025          |           |                       |                |
| Carotid plaques | 4.7 (1.1–20)     | 0.034          |           |                       |                |
| NODAT       | 6.8 (1.9–25)          | 0.003          |           |                       |                |
| Baseline T-cholesterol | 5.9 (1.7–20) | 0.005          |           |                       |                |
| Group II (vs. Group I) | 4.9 (1.1–23) | 0.045          |           |                       |                |

**Abbreviations:** c-IMT, carotid intima-media thickness; KT, kidney transplantation; VC, vascular calcifications; NODAT, new onset diabetes after transplantation; PD, peritoneal dialysis; T-cholesterol, total cholesterol. Group II, patients who showed an increase to the highest tertile or who maintained both values within the highest tertile; Group I, patients who showed a reduction to a lower tertile or who maintained both values within the lower or the middle tertile.

*Because the number of events was few, this analysis was performed entering risk factors two by two.*

\[ \text{doi:10.1371/journal.pone.0129083.t004} \]
Inflammation-related endothelial dysfunction is associated with CVD, including subclinical atheromatosis, in the general population and renal patients [3, 22]. However, the precise relationship between c-IMT measurements and the vascular generation of molecules involved in the pathogenesis of atheromatosis of unselected KT candidates has not been studied. Interestingly, we found a significantly higher expression of VCAM-1 in the IEA of patients in the highest c-IMT tertile. Accordingly, c-IMT measurements correlated with VCAM-1 levels and the degree of arterial lumen reduction. Importantly, VCAM-1 protein levels were independently associated with baseline c-IMT in multiple regression analysis, suggesting that this parameter may be an early surrogate marker of atheromatosis in KT candidates, mainly when other risk factors concur. Indeed, risk factors for atherosclerosis such as age, diabetes, smoking and vascular calcifications were overrepresented among recipients in the highest c-IMT tertile. In agreement with our findings, previous studies have reported an independent significantly association between adhesion molecules and c-IMT measurements in other inflammatory states, including CKD [5, 23–25], corroborating the role of these molecules in the development of atherosclerosis-associated endothelial activation.

Although no significantly higher expression of IL-6 and MCP-1 was observed among patients in the highest c-IMT tertile, we cannot rule out the role of other proinflammatory cytokines for the development of atheromatosis in renal patients [5, 17, 26]. Indeed, we also found a strong correlation between all the inflammatory markers measured in the artery wall (data not shown), but VCAM-1 expression stood out. Thus, a pathogenic mechanism accounting for the role of adhesion molecules, especially VCAM-1, in renal patients seems plausible. In the presence of uremia, the clustering of risk factors leads to endothelial activation and the release of pro-inflammatory cytokines in the artery wall, initiating the mechanisms leading to the development of atherosclerosis. Cytokine activation produces dramatic up-regulation of adhesion molecule expression on the cell surface by SMCs resident in the intima layer with a synthetic phenotype, thus participating in cell-to-cell interaction and the recruitment of inflammatory cells [27]. Finally, activation of these inflammatory molecules induces the generation of fibrosis as the result of a final common pathway, perpetuating the inflammatory environment in the atherosclerotic lesion [28]. The fact that production of VCAM-1 correlated with more severe vascular lesions, e.g. increased arterial narrowing or more carotid plaques in the presence of abundant SMA-positive cells and collagen fibers in the intima layer, supports the role of VCAM-1 as a major marker of atherosclerosis, and that it is also necessary for neointima formation due to SMC migration [29, 30]. A plausible explanation for the correlation between VCAM-1 levels and the severity of vascular lesions could involve the induction of SMC migration to the neointima by VCAM-1 and the switching from a contractile to a synthetic SMC phenotype, leading to more severe lesions and higher production of cytokines and adhesion molecules. Histological studies in animal models of atheromatosis have shown that ICAM-1 immunostaining is stronger in the endothelium and weaker in intimal cells than VCAM-1, staining of which is much more restricted to lesions and abundant in neointimal cells [31]. These differential requirements for VCAM-1 and ICAM-1 in the formation of atherosclerotic lesions may indicate different roles for these molecules, with VCAM-1 playing a dominant role at the site of the lesion [32]. In agreement with this view, the patients in the highest VCAM-1 tertile experienced a higher degree of lumen reduction of IEA, and this luminal narrowing correlated with the vascular VCAM-1 protein levels. This agrees with the major proportion of cardiovascular disease and carotid plaques observed in our patients in the highest VCAM-1 tertile. The fact that soluble VCAM-1, but not ICAM-1, remained the only predictor of c-IMT in hypertensive patients with peripheral vascular disease [33] supports this hypothesis. Indeed, when we assessed longitudinally the impact of inflammatory markers in the IEA on survival after KT, intravascular VCAM-1 protein levels were a strong predictor of death in our
multivariate Cox analysis. Accordingly, VCAM-1 protein levels were significantly higher in our patients with carotid plaques, which are prognostic factors for CVD in CKD [12, 34]. Although elevated soluble VCAM-1 is associated with post-transplant mortality, its expression in the artery wall was not investigated [9, 10]. These findings suggest that this molecule is an essential mediator in atheromatosis-related endothelial activation and dysfunction after KT. In support of this view, suppression of VCAM-1 has been shown to protect against atherosclerosis in an animal model [30, 35].

Successful KT may not completely ameliorate subclinical atheromatosis, possibly reflecting significant pre-existing vascular abnormalities. Thus, an increased baseline c-IMT may be a limiting factor for regression of c-IMT after KT, mainly in the presence of risk factors for atheromatosis. Indeed, nearly 50% of our patients showed an increase or maintenance of high c-IMT 1-year post-KT and a worse cardiovascular profile was observed in these patients, mainly due to glucose metabolism disorders. Additionally, baseline c-IMT, NODAT and triglycerides were independently associated with post-transplant c-IMT. Accordingly, individuals with a persistently high or increased c-IMT experienced a higher mortality in the univariate analysis. These findings agree with previous studies [13, 14, 16], and underscore the enhanced cardiovascular risk in this population, especially due to immunosuppressant side effects. Both immunosuppression-related insulin resistance and hyperglycemia may accelerate the development of atherosclerosis by triggering inflammation pathways leading to increased mortality over time, as reported [36–38]. The fact that c-IMT improves after successful pancreas transplantation within 2 years of the procedure [39] supports this view.

We found no relationship between pro-inflammatory molecules and final c-IMT in either non-diabetic or diabetic patients. A reduction in endothelial biomarkers such as VCAM-1 has been shown in KT recipients, suggesting improvement of endothelial injury [40, 41], but endothelial function evaluated by brachial artery flow-mediated dilation was not assessed [3]. Whether reduction of inflammation could translate into improvement of post-transplant CVD remains unanswered.

Our study has limitations. We did not assess the plasma levels of the cytokines and adhesion molecules evaluated. Plasma cytokine levels may vary greatly under certain uremia-related clinical conditions while soluble cellular adhesion molecules, particularly VCAM-1, have been found to be markers of post-transplant mortality [9]. Given that activated endothelial cells may be a major source of soluble VCAM-1 by cleavage from the plasma membrane, direct assessment of both pro-inflammatory gene activation and protein secretion in the artery wall may better highlight the pathways of inflammatory-related atheromatosis at the site of lesion, especially in high-risk renal patients. We performed a rigorous and accurate molecular and histological analysis, which provide reliability to our results. No significant differences were observed in gene expression of proinflammatory markers, though there were differences in protein secretion. We can only speculate about the dissociation between VCAM-1 mRNA and protein levels. Differences in protein and mRNA half-lives as well as post-translational regulation could be involved. We also have to take into account biological mechanisms such as cytokine secretion and the action of sheddases on adhesion molecules, which release the proteins to the circulation and alter the amounts of proteins in the artery wall. In addition, we cannot rule out that other inflammatory molecules, especially C-reactive protein, not determined in this study may be involved in the development of atheromatosis, as reported in CKD patients [42]. This is certainly a limitation of our study and it deserves future research. In addition, we did not perform physiological measures of endothelial function to complement VCAM-1 measurements, which represents another limitation of our study. Also, histological findings in the IEA may not be generalizable to other arterial territories. Nevertheless, autopsies of elderly patients who died of noncardiac diseases have documented that coronary arteries and IEA undergo
progressive narrowing with age as a result of atheromatous histological lesions [43, 44], as in our study. Finally, the relatively small sample means additional studies are needed to enhance understanding of atheromatosis-related inflammatory pathways in renal patients.

Conclusions
A worse cardiovascular profile and a higher VCAM-1 protein levels in the artery wall are associated with subclinical atheromatosis in KT candidates. This could lead to increased post-transplant mortality. Successful KT does not fully normalize c-IMT post-transplantation. Because both pre-transplant c-IMT and NODAT may condition an increased c-IMT post-transplantation, strict metabolic control could improve survival after KT.

Supporting Information
S1 Fig. c-IMT measurements, fasting glucose levels and VCAM-1 protein levels. Relationship between c-IMT measurements, fasting glucose levels and VCAM-1 protein levels in the artery wall at baseline (A and B) and at the first post-transplant year (C and D).

S2 Fig. Overall Kaplan-Meier curves according to baseline c-IMT tertiles. Log-rank analysis 7.3, \(P = 0.025\). Log-rank test for comparison of survival between c-IMT tertiles (T3 vs. T1, \(P = 0.006\); T2 vs. T1, \(P = 0.068\); T3 vs. T2, \(P = 0.309\)).

S3 Fig. Overall Kaplan-Meier curves according to VCAM-1 protein tertiles. Log-rank analysis 4.8, \(P = 0.089\). Log-rank test for comparison of survival between VCAM-1 tertiles (T3 vs. T1, \(P = 0.035\); T2 vs. T1, \(P = 0.202\); T3 vs. T2, \(P = 0.415\)).

Acknowledgments
The authors thank the Canarian renal transplantation team for their collaboration. We also thank Pedro Ruiz-Esteban for technical assistance and Ian Johnstone for linguistic assistance in the preparation of the text.

Author Contributions
Conceived and designed the experiments: DH JT. Performed the experiments: JT ES SP. Analyzed the data: DH SP JT ES. Contributed reagents/materials/analysis tools: MR JMG-P. Wrote the paper: DH JT ES AT.

References
1. Ortiz A, Covic A, Fliser D, Fouque D, Goldsmith D, Kanbay M, et al. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet. 2014; 383(9931):1831–43. Epub 2014/05/27. S0140-6736(14)60384-6 [pii] doi:10.1016/S0140-6736(14)60384-6 PMID: 24856028.
2. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010; 375(9731):2073–81. Epub 2010/05/21. S0140-6736(10)60674-5 [pii] doi: 10.1016/S0140-6736(10)60674-5 PMID: 20483451; PubMed Central PMCID: PMC3993088.
3. Recio-Mayoral A, Banerjee D, Streather C, Kaski JC. Endothelial dysfunction, inflammation and atherosclerosis in chronic kidney disease—a cross-sectional study of predialysis, dialysis and kidney-transplantation patients. Atherosclerosis. 2011; 216(2):446–51. Epub 2011/03/19. S0021-9150(11)00173-0 [pii] doi: 10.1016/j.atherosclerosis.2011.02.017 PMID: 21414625.
Roe P, Wolfe M, Joffe M, Rosas SE. Inflammation, coronary artery calcification and cardiovascular disease. Nephrol Dial Transplant. 2012; 27(2):427–33. doi:10.1093/ndt/gfr263 PMID:19821655.

van Ree RM, Oterdoom LH, de Vries AP, Homan van der Heide JJ, van Son WJ, Navis G, et al. Circulating markers of endothelial dysfunction interact with proteinuria in predicting mortality in renal transplant recipients. Transplantation. 2008; 86(12):1713–9. Epub 2008/12/24. doi:10.1097/TP.0b013e318190dd45 PMID:19104410.

Benedetto FA, Tripepi G, Mallamaci F, Zoccali C. Rate of atherosclerotic plaque formation predicts cardiovascular events in incident renal disease: a predictor of outcome. Nephrol Dial Transplant. 2006; 21(6):1603–10. Epub 2006/02/16. gfl005 [pii] doi:10.1093/ndt/gfl005 PMID:16476720.

Niida T, Isoda K, Kitagaki M, Ishigami N, Adachi T, Matsubara O, et al. IkappaBNS regulates interleukin-6 production and inhibits neointimal formation after vascular injury in mice. Cardiovasc Res. 2012; 93(2):371–9. Epub 2011/12/03. cvr323 [pii] doi:10.1093/cvr/cvr323 PMID:22135163.

Connolly GM, Cunningham R, McNamee PT, Young IS, Maxwell AP. Elevated soluble cellular adhesion molecules are associated with increased mortality in a prospective cohort of renal transplant recipients. BMC Nephrol. 2011; 12:23. Epub 2011/05/24. 1471-2369-12-23 [pii] doi:10.1186/1471-2369-12-23 PMID:21600046; PubMed Central PMCID: PMC3120748.

van Ree RM, Oterdoom LH, de Vries AP, Homan van der Heide JJ, van Son WJ, Navis G, et al. Circulating markers of endothelial dysfunction interact with proteinuria in predicting mortality in renal transplant recipients. Transplantation. 2008; 86(12):1713–9. Epub 2008/12/24. doi:10.1097/TP.0b013e318190dd45 PMID:19104410.

Roe P, Wolfe M, Joffe M, Rosas SE. Inflammation, coronary artery calcification and cardiovascular events in incident renal transplant recipients. Atherosclerosis. 2010; 212(2):589–94. Epub 2010/10/12. S0021-9150(10)00394-1 [pii] doi:10.1016/j.atherosclerosis.2010.05.016 PMID:20934074; PubMed Central PMCID: PMC2953547.

Benedetto FA, Tripepi G, Mallamaci F, Zoccali C. Rate of atherosclerotic plaque formation predicts cardiovascular events in ESRD. J Am Soc Nephrol. 2008; 19(4):757–63. Epub 2008/01/01. ASN.2007070813 [pii] doi:10.1681/ASN.2007070813 PMID:18184855; PubMed Central PMCID: PMC2390959.

Alvarez A, Fernandez J, Porrini E, Delgado P, Pitti S, Vega MJ, et al. Carotid atheromatosis in nondiabetic renal transplant recipients: the role of prediabetic glucose homeostasis alterations. Transplantation. 2007; 84(7):870–5. doi:10.1097/TOP.0b013e318190dd45 PMID:17984840.

De Lima JJ, Vieira ML, Viviani LF, Medeiros CJ, Ianhez LE, Kopel L, et al. Long-term impact of renal transplantation on carotid artery properties and on ventricular hypertrophy in end-stage renal failure patients. Nephrol Dial Transplant. 2002; 17(4):645–51. Epub 2002/03/28. PMID:11917059.

Gerhart MK, Seiler S, Grun OS, Rogacev KS, Fliser D, Heine GH. Indices of systemic atherosclerosis are superior to ultrasound resistance indices for prediction of allograft survival. Nephrol Dial Transplant. 2010; 25(4):1294–300. Epub 2009/12/01. gfp631 [pii] doi:10.1093/ndt/gfp631 PMID:19945953.

Osorio JM, Ferreyra C, Perez JM, Moreno JM, Osuna A. Prediabetic States, subclinical atheromatosis, and oxidative stress in renal transplant patients. Transplant Proc. 2009; 41(6):2148–50. doi:10.1016/j.transproceed.2009.06.002 PMID:19715858.

Sánchez-Escudero A, Pastor MC, Bayés B, Morales-Indiano C, Troya M, Dolea M, et al. Inflammation, metalloproteinases, and growth factors in the development of carotid atheromatosis in renal transplant patients. Transplant Proc. 2010; 42(8):2905–7. doi:10.1016/j.transproceed.2010.07.076 PMID:20970566.

Cofan F, Arias M, Nunez I, Cofan M, Corbella E, Rosich E, et al. Impact of carotid atherosclerosis as assessed by B-mode ultrasonography on the evolution of kidney transplantation. Transplant Proc. 2007; 39(7):2236–8. Epub 2007/09/25. S0041-1345(07)00778-6 [pii] doi:10.1016/j.transproceed.2007.06.062 PMID:17889149.

Herandez D, Perez G, Marrero D, Porini E, Rufino M, Gonzalez-Posada JM, et al. Early association of low-grade albuminuria and allograft dysfunction predicts renal transplant outcomes. Transplantation. 2012; 93(3):297–303. doi:10.1097/TP.0b013e318236c0a7 PMID:22284119.

Hellemans J, Mortier G, De Paepe A, Speleman F, Vandemeule J. qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data.
22. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003; 107(3):499–511. Epub 2003/01/29. PMID: 12551878.

23. Ross AC, O’Riordan MA, Storer N, Dogra V, Comcee GA. Heightened inflammation is linked to carotid intima-media thickness and endothelial activation in HIV-infected children. Atherosclerosis. 2010; 211(2):492–8. Epub 2010/05/18. S0021-9150(10)00262-5 [pii] doi:10.1016/j.atherosclerosis.2010.04.008 PMID: 20471650.

24. Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Gotto AM Jr, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation. 1997; 96(12):4219–25. Epub 1998/01/07. PMID: 9416885.

25. Papagianni A, Kalovoulou M, Kirmizis D, Vainas A, Belechri AM, Alexopoulos E, et al. Carotid atherosclerosis is associated with inflammation and endothelial cell adhesion molecules in chronic haemodialysis patients. Nephrol Dial Transplant. 2003; 18(1):113–9. Epub 2002/12/14. PMID: 12490968.

26. Papagianni A, Alexopoulos E, Giampalis P, Gionanlis L, Belechri AM, Koukoudis P, et al. Circulating levels of ICAM-1, VCAM-1, and MCP-1 are increased in haemodialysis patients: association with inflammation, dyslipidaemia, and vascular events. Nephrol Dial Transplant. 2002; 17(3):435–41. Epub 2002/02/28. PMID: 11865089.

27. Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood. 1994; 84(7):2068–101. Epub 1994/10/01. PMID: 7522621.

28. O’Brien KD, McDonald TO, Chait A, Allen MD, Alpers CE. Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. Circulation. 1996; 93(4):672–82. Epub 1996/02/15. PMID: 8640995.

29. Petersen EJ, Miyoshi T, Yuan Z, Hirohata S, Li JZ, Shi W, et al. siRNA silencing reveals role of vascular cell adhesion molecule-1 in vascular smooth muscle cell migration. Atherosclerosis. 2008; 198(2):301–6. doi:10.1016/j.atherosclerosis.2007.10.015 PMID: 18054358; PubMed Central PMCID: PMC2396871.

30. Oguchi S, Dimayuga P, Zhu J, Chyu KY, Yano J, Shah PK, et al. Monoclonal antibody against vascular cell adhesion molecule-1 inhibits neointimal formation after perivascular carotid artery injury in genetically hypercholesterolemic mice. Arterioscler Thromb Vasc Biol. 2000; 20(7):1729–36. PMID: 10894810.

31. Iiyama K, Hajar L, Iiyama M, Li H, DiChiara M, Medoff BD, et al. Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation. Circ Res. 1999; 85(2):199–207. PMID: 10417402.

32. Cybulsky MI, Iiyama K, Li H, Zhu S, Chen M, Iiyama M, et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest. 2001; 107(10):1255–62. doi:10.1172/JCI11871 PMID: 11375415; PubMed Central PMCID: PMC209299.

33. De Caterina R, Basta G, Lazzerini G, Dell’Omo G, Petrucci R, Morale M, et al. Soluble vascular cell adhesion molecule-1 as a biohumoral correlate of atherosclerosis. Arterioscler Thromb Vasc Biol. 1997; 17(11):2646–54. PMID: 9409238.

34. Coll B, Betriu A, Martinez-Alonso M, Amoedo ML, Arcidiacono MV, Borras M, et al. Large artery calcification on dialysis patients is located in the intima and related to atherosclerosis. Clin J Am Soc Nephrol. 2011; 6(2):303–10. Epub 2010/10/12. CJN.04290510 [pii] doi:10.2215/CJN.04290510 PMID: 20930091; PubMed Central PMCID: PMC3052220.

35. Park JG, Ryu SY, Jung IH, Lee YH, Kang KJ, Lee MR, et al. Evaluation of VCAM-1 antibodies as therapeutic agent for atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis. 2013; 226(2):356–63. doi:10.1016/j.atherosclerosis.2012.11.029 PMID: 23245509.

36. Genis BB, Granada ML, Alonso N, Lauzurica R, Jimenez JA, Barluenga E, et al. Ghrelin, glucose homeostasis, and carotid intima media thickness in kidney transplantation. Transplantation. 2007; 84(10):1248–54. Epub 2007/12/01. doi:10.1097/TP.0b013e32884267d6; PubMed Central PMCID: PMC20711270-00006 [pii] doi:10.1097/TP.0b013e32884267d6; PubMed Central PMCID: PMC20711270-00006 [pii]. PMID: 18049109.

37. Porriti E, Delgado P, Bigo C, Alvarez A, Cobo M, Checa MD, et al. Impact of metabolic syndrome on graft function and survival after cadaveric renal transplantation. American journal of kidney diseases:
38. Esposito C, Fasoli G, Plati AR, Bellotti N, Conte MM, Cornacchia F, et al. Long-term exposure to high glucose up-regulates VCAM-induced endothelial cell adheriveness to PBMC. Kidney Int. 2001; 59 (5):1842–9. Epub 2001/04/25. kid688 [pii] doi: 10.1046/j.1523-1755.2001.0590051842.x PMID: 11318955.

39. Larsen JL, Colling CW, Ratansuwan T, Burkman TW, Lynch TG, Erickson JM, et al. Pancreas transplantation improves vascular disease in patients with type 1 diabetes. Diabetes Care. 2004; 27 (7):1706–11. Epub 2004/06/29. doi: 27/7/1706 [pii]. PMID: 15220250.

40. Al-Massarani G, Vacher-Coponat H, Paul P, Widemann A, Arnaud L, Loundou A, et al. Impact of immunosuppressive treatment on endothelial biomarkers after kidney transplantation. Am J Transplant. 2008; 8(11):2360–7. Epub 2008/10/18. AJT2399 [pii] doi: 10.1111/j.1600-6143.2008.02399.x PMID: 18925903.

41. Bueti J, Rush D, Tangri N, Mandelzweig K, Xu Y, Hiebert B, et al. Effect of time on dialysis and renal transplantation on endothelial function: a longitudinal analysis. Transplantation. 2014; 98(10):1060–8. Epub 2014/06/01. doi: 10.1097/TP.0000000000000180 PMID: 24879381.

42. Yilmaz MI, Stenvinkel P, Sonmez A, Saglam M, Yaman H, Kilic S, et al. Vascular health, systemic inflammation and progressive reduction in kidney function; clinical determinants and impact on cardiovascular outcomes. Nephrol Dial Transplant. 2011; 26(11):3537–43. doi: 10.1093/ndt/gfr081 PMID: 21378154.

43. Barry M, Touati G, Chardon K, Laude M, Libert JP, Sevestre H. Histologic study of coronary, radial, ulnar, epigastric and internal thoracic arteries: application to coronary artery bypass grafts. Surg Radiol Anat. 2007; 29(4):297–302. Epub 2007/05/17. doi: 10.1007/s00276-007-0214-4 PMID: 17505775.

44. van Son JA, Smedts FM, Yang CQ, Mravunac M, Falk V, Mohr FW, et al. Morphometric study of the right gastroepiploic and inferior epigastric arteries. Ann Thorac Surg. 1997; 63(3):709–15. Epub 1997/03/01. doi: 10.1016/S0003-4975(96)011150 [pii]. PMID: 9066389.